Development and validation of a purification system for functional full-length human SR-B1 and CD36
Hayley R Powers1, Shawn E Jenjak1, Brian F Volkman1
1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Insights
Researchers successfully purified full-length scavenger receptor class B type 1 (SR-B1) and CD36 proteins. These purified receptors maintain normal function, enabling new studies into lipoprotein metabolism and atherosclerotic disease.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Scavenger receptor class B type 1 (SR-B1) and CD36 are crucial for lipoprotein metabolism and atherosclerosis.
- Previous structural studies were limited to receptor fragments, hindering a full understanding of their function.
Purpose of the Study:
- To express and purify full-length human SR-B1 and CD36.
- To confirm the functional integrity and stability of the purified receptors.
- To establish tools for future structural and functional investigations of these key receptors.
Main Methods:
- Expression of full-length human SR-B1 and CD36 in an insect cell system (Spodoptera frugiperda).
- Purification using optimized schemes, confirmed by SDS-PAGE.
- Functional assays including lipoprotein binding and lipid transport.
- Stability assessment via thermal shift assay.
- Ligand-binding affinity determined by microscale thermophoresis.
Main Results:
- Successful expression and purification of functional full-length SR-B1 and CD36.
- Receptors retained native functions, including lipoprotein binding and oligomerization.
- Purified receptors demonstrated stability for up to 6 weeks.
- Binding affinities for native ligands (HDL for SR-B1, oxLDL for CD36) were confirmed and unaffected by glycosylation status.
Conclusions:
- This study provides the first purified full-length SR-B1 and CD36, crucial tools for advancing scavenger receptor research.
- The findings validate the functional integrity and stability of these purified proteins.
- These results pave the way for detailed structural studies and a deeper understanding of their roles in disease.
Abstract:
Scavenger receptor class B type 1 (SR-B1) and CD36 are both members of the class B scavenger receptor family that play important roles in lipoprotein metabolism and atherosclerotic disease. SR-B1 is the primary receptor for high-density lipoproteins, while CD36 is the receptor responsible for the internalization of oxidized low-density lipoproteins. Despite their importance, class B scavenger receptor structure has only been studied by functional domain or peptide fragments-there are currently no reports of utilizing purified full-length protein. Here we report the successful expression and purification of full-length human SR-B1 and CD36 using an Spodoptera frugiperda insect cell system. We demonstrate that both SR-B1 and CD36 retained their normal functions in Spodoptera frugiperda cells, including lipoprotein binding, lipid transport, and the formation of higher order oligomers in the plasma membrane. Purification schemes for both scavenger receptors were optimized and their purity was confirmed by SDS-PAGE. Both purified scavenger receptors were assessed for stability by thermal shift assay and shown to maintain stable melting temperatures up to 6 weeks post-purification. Microscale thermophoresis was used to demonstrate that purified SR-B1 and CD36 were able to bind their native lipoprotein ligands. Further, there was no difference in affinity of SR-B1 for high-density lipoprotein or CD36 for oxidized low-density lipoprotein, when comparing glycosylated and deglycosylated receptors. These studies mark a significant step forward in creating physiologically relevant tools to study scavenger receptor function and lay the groundwork for future functional studies and determination of receptor structure.
More Related Videos
11:21Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs
Published on: September 10, 2017
13:14Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
